{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:34:53Z","timestamp":1789644893517,"version":"4.0.0"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014996","name":"Health Commission of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017531","name":"Medical and Health Research Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2022KY529"],"award-info":[{"award-number":["2022KY529"]}],"id":[{"id":"10.13039\/501100017531","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bcp.2025.117018","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T02:39:34Z","timestamp":1748918374000},"page":"117018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["B cell-targeted therapies in systemic lupus erythematosus: Current status and perspectives"],"prefix":"10.1016","volume":"239","author":[{"given":"Lanlan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuling","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4307-0845","authenticated-orcid":false,"given":"Kaiqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.117018_b0005","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/S0140-6736(19)30237-5","article-title":"Management strategies and future directions for systemic lupus erythematosus in adults","volume":"393","author":"Durcan","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2025.117018_b0010","doi-asserted-by":"crossref","first-page":"ITC81","DOI":"10.7326\/AITC202006020","article-title":"Systemic lupus erythematosus","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bcp.2025.117018_b0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update \u03bfn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bcp.2025.117018_b0020","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1146\/annurev-med-043021-032611","article-title":"Systemic lupus erythematosus: new diagnostic and therapeutic approaches","volume":"74","author":"Lazar","year":"2023","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.bcp.2025.117018_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102873","article-title":"B cell-targeted therapies in systemic lupus erythematosus","volume":"132","author":"Arbitman","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.bcp.2025.117018_b0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2017.07.010","article-title":"B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus","volume":"186","author":"Tanaka","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.bcp.2025.117018_b0035","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nrrheum.2016.158","article-title":"Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE","volume":"12","author":"D\u00f6rner","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.bcp.2025.117018_b0040","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.3390\/ijms20236021","article-title":"Multiple functions of B cells in the pathogenesis of systemic lupus erythematosus","volume":"20","author":"Ma","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bcp.2025.117018_b0045","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.4049\/jimmunol.172.6.3422","article-title":"Distinct profiles of human B cell effector cytokines: a role in immune regulation?1","volume":"172","author":"Duddy","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2025.117018_b0050","article-title":"What\u2019s new in the treatment of systemic lupus erythematosus","volume":"8","author":"Liossis","year":"2021","journal-title":"Front Med (lausanne)"},{"key":"10.1016\/j.bcp.2025.117018_b0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/abt\/tbae033","article-title":"Current use and development of monoclonal antibodies for the treatment of systemic lupus erythematosus: a review","volume":"8","author":"Blagov","year":"2025","journal-title":"Antibody Therapeutics"},{"key":"10.1016\/j.bcp.2025.117018_b0060","first-page":"73ps9","article-title":"Dissecting the immune cell mayhem that drives lupus pathogenesis","author":"Craft","year":"2011","journal-title":"Sci Transl Med 3"},{"key":"10.1016\/j.bcp.2025.117018_b0065","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2025.117018_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102861","article-title":"Autoantibodies in systemic lupus erythematosus: from immunopathology to therapeutic target","volume":"132","author":"Lou","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.bcp.2025.117018_b0075","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4049\/jimmunol.171.1.489","article-title":"Short term administration of costimulatory blockade and cyclophosphamide induces Remission of systemic lupus erythematosus nephritis in NZB\/W F1 mice by a mechanism downstream of renal immune complex Deposition1","volume":"171","author":"Schiffer","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2025.117018_b0080","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1126\/science.279.5353.1052","article-title":"Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis","volume":"279","author":"Clynes","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.bcp.2025.117018_b0085","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1086\/302767","article-title":"Genome screening in human systemic lupus erythematosus: results from a second Minnesota cohort and combined analyses of 187 sib-pair families","volume":"66","author":"Gaffney","year":"2000","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.bcp.2025.117018_b0090","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bcp.2025.117018_b0095","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.immuni.2018.03.027","article-title":"T follicular helper cell-germinal center B cell Interaction strength regulates entry into plasma cell or recycling germinal center cell fate","volume":"48","author":"Ise","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2025.117018_b0100","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.kint.2017.08.031","article-title":"Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis","volume":"93","author":"Fu","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.bcp.2025.117018_b0105","doi-asserted-by":"crossref","DOI":"10.1172\/JCI149095","article-title":"Meant to B: B cells as a therapeutic target in systemic lupus erythematosus","volume":"131","author":"Atisha-Fregoso","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2025.117018_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2020.100075","article-title":"Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and fc\u03b3 receptor IIb in non-autoimmune-prone and SLE-prone mice","volume":"4","author":"Chu","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.bcp.2025.117018_b0115","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s12325-024-03067-6","article-title":"Pharmacokinetics, pharmacodynamics, bioavailability, and immunogenicity of obexelimab following subcutaneous administration in healthy japanese and non-japanese volunteers","volume":"42","author":"Wang","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.bcp.2025.117018_b0120","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/art.42652","article-title":"Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co\u2010expression patterns: a double\u2010blind, randomized, placebo\u2010controlled, phase 2 trial","volume":"75","author":"Merrill","year":"2023","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.bcp.2025.117018_b0125","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1016\/j.apsb.2024.06.024","article-title":"A rationally designed CD19 monoclonal antibody-triptolide conjugate for the treatment of systemic lupus erythematosus","volume":"14","author":"Wang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bcp.2025.117018_b0130","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-Severely active systemic lupus erythematosus","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bcp.2025.117018_b0135","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"LUNAR Investigator Group, efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"2024","key":"10.1016\/j.bcp.2025.117018_b0140","first-page":"15","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bcp.2025.117018_b0145","article-title":"The safety and efficacy of rituximab and belimumab in systemic lupus erythematosus: a systematic review","volume":"15","author":"Abid","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.bcp.2025.117018_b0150","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/ndt\/gfaa117","article-title":"Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results","volume":"36","author":"Kraaij","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.bcp.2025.117018_b0155","first-page":"1206","article-title":"Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies","volume":"9","author":"Hutas","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.bcp.2025.117018_b0160","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bcp.2025.117018_b0165","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bcp.2025.117018_b0170","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1093\/rheumatology\/keac150","article-title":"Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab","volume":"61","author":"Arnold","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bcp.2025.117018_b0175","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/rheumatology\/key042","article-title":"Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab","volume":"57","author":"Masoud","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bcp.2025.117018_b0180","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1177\/0961203319881500","article-title":"Successful treatment of systemic lupus erythematosus-related refractory autoimmune hemolytic anemia with ofatumumab","volume":"28","author":"Poulet","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.bcp.2025.117018_b0185","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/nrrheum.2014.54","article-title":"The role of CD22 and siglec-G in B-cell tolerance and autoimmune disease","volume":"10","author":"M\u00fcller","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.bcp.2025.117018_b0190","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3389\/fimmu.2018.02235","article-title":"CD22: a regulator of innate and adaptive B cell responses and autoimmunity","volume":"9","author":"Clark","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.bcp.2025.117018_b0195","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/rheumatology\/ket378","article-title":"Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006","volume":"53","author":"Strand","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bcp.2025.117018_b0200","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13075-015-0686-2","article-title":"Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-\u03b1, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients","volume":"17","author":"Fleischer","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.bcp.2025.117018_b0205","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/jcp.30760","article-title":"Effect of CD38 on B-cell function and its role in the diagnosis and treatment of B-cell-related diseases","volume":"237","author":"Zeng","year":"2022","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.bcp.2025.117018_b0210","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2024.2399430","article-title":"Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis","volume":"29","author":"Jiang","year":"2024","journal-title":"Hematology"},{"key":"10.1016\/j.bcp.2025.117018_b0215","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2025.117018_b0220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.645478","article-title":"Restoration of NK cell cytotoxic function with elotuzumab and daratumumab promotes elimination of circulating plasma cells in patients with SLE","volume":"12","author":"Humbel","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.bcp.2025.117018_b0225","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL system in SLE pathogenesis","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.bcp.2025.117018_b0230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cellimm.2009.10.004","article-title":"BAFF overexpression promotes anti-dsDNA B-cell maturation and antibody secretion","volume":"261","author":"Thorn","year":"2010","journal-title":"Cell Immunol"},{"key":"10.1016\/j.bcp.2025.117018_b0235","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/art.23678","article-title":"Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus","volume":"58","author":"Petri","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bcp.2025.117018_b0240","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","article-title":"BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth","volume":"189","author":"Schneider","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.bcp.2025.117018_b0245","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.285.5425.260","article-title":"BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator","volume":"285","author":"Moore","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.bcp.2025.117018_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (SLE)","volume":"20","author":"M\u00f6ckel","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.bcp.2025.117018_b0255","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: a review in systemic lupus erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2025.117018_b0260","article-title":"Belimumab for systemic lupus erythematosus","author":"Singh","year":"2021","journal-title":"Cochrane Database Syst Rev 2"},{"key":"10.1016\/j.bcp.2025.117018_b0265","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12016-018-8675-2","article-title":"Effectiveness, tolerability, and safety of belimumab in patients with refractory SLE: a review of observational clinical-practice-based studies","volume":"54","author":"Trentin","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.bcp.2025.117018_b0270","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaf145","article-title":"Belimumab efficacy in mucocutaneous manifestations of systemic lupus erythematosus: a large post hoc analysis of five phase III clinical trials","author":"Grosso","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.bcp.2025.117018_b0275","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2025.117018_b0280","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2215\/CJN.02520322","article-title":"Safety and efficacy of belimumab in patients with lupus nephritis","volume":"17","author":"Furie","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.bcp.2025.117018_b0285","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.bcp.2025.117018_b0290","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","article-title":"Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Isenberg","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2025.117018_b0295","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","volume":"75","author":"Merrill","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bcp.2025.117018_b0300","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coi.2021.06.009","article-title":"Function, occurrence and inhibition of different forms of BAFF","volume":"71","author":"Eslami","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.bcp.2025.117018_b0305","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s13075-015-0741-z","article-title":"Treatment of systemic lupus erythematosus patients with the BAFF antagonist \u201cpeptibody\u201d blisibimod (AMG 623\/A-623): results from randomized, double-blind phase 1a and phase 1b trials","volume":"17","author":"Stohl","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.bcp.2025.117018_b0310","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","article-title":"A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study","volume":"74","author":"Furie","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2025.117018_b0315","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/annrheumdis-2018-213032","article-title":"Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial","volume":"77","author":"Merrill","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2025.117018_b0320","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2147\/DDDT.S114552","article-title":"Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date","volume":"11","author":"Lenert","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bcp.2025.117018_b0325","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2025.117018_b0330","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1177\/09612033221097812","article-title":"Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: a self-controlled before-after trial","volume":"31","author":"Sun","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.bcp.2025.117018_b0335","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bcp.2025.117018_b0340","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-001074","article-title":"Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study","volume":"10","author":"Jin","year":"2023","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.bcp.2025.117018_b0345","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bcp.2025.117018_b0350","first-page":"266","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus, arthritis","volume":"70","author":"Merrill","year":"2018","journal-title":"Rheumatol"},{"key":"10.1016\/j.bcp.2025.117018_b0355","article-title":"Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme","volume":"3","author":"Gordon","year":"2019","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.bcp.2025.117018_b0360","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41584-024-01210-9","article-title":"Opportunities and limitations of B cell depletion approaches in SLE","volume":"21","author":"Stockfelt","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.bcp.2025.117018_b0365","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3390\/pharmaceutics16091176","article-title":"Biologics in systemic lupus erythematosus: recent evolutions and benefits","volume":"16","author":"Kundnani","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bcp.2025.117018_b0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2021.104420","article-title":"Distinct roles of ICOS and CD40L in human T-B cell adhesion and antibody production","volume":"368","author":"Liu","year":"2021","journal-title":"Cell Immunol"},{"key":"10.1016\/j.bcp.2025.117018_b0375","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/rheumatology\/keh724","article-title":"Expression and function of inducible costimulator on peripheral blood T cells in patients with systemic lupus erythematosus","volume":"44","author":"Yang","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.bcp.2025.117018_b0380","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00063030-200418020-00003","article-title":"Costimulation blockade in the treatment of rheumatic diseases","volume":"18","author":"Liossis","year":"2004","journal-title":"BioDrugs"},{"key":"10.1016\/j.bcp.2025.117018_b0385","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1136\/annrheumdis-2017-211388","article-title":"Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles","volume":"76","author":"Chamberlain","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bcp.2025.117018_b0390","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/annrheumdis-2018-214729","article-title":"Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study","volume":"78","author":"Visvanathan","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bcp.2025.117018_b0395","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/1744666X.2021.1976146","article-title":"Clinical relevance of T follicular helper cells in systemic lupus erythematosus","volume":"17","author":"Nakayamada","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.bcp.2025.117018_b0400","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000146","article-title":"Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus","volume":"3","author":"Sullivan","year":"2016","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.bcp.2025.117018_b0405","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/cpdd.36","article-title":"Randomized, double-blind, placebo-controlled, parallel-group QT\/QTc study to evaluate the electrophysiologic effects of THC\/CBD spray","volume":"2","author":"Sellers","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.bcp.2025.117018_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106221","article-title":"CTLA-4: from mechanism to autoimmune therapy","volume":"80","author":"Hosseini","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2025.117018_b0415","first-page":"379","article-title":"Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study, arthritis","volume":"66","author":"Furie","year":"2014","journal-title":"Rheumatol."},{"key":"10.1016\/j.bcp.2025.117018_b0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107612","article-title":"A review on applications of abatacept in systemic rheumatic diseases","volume":"96","author":"Liu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.bcp.2025.117018_b0425","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2025.117018_b0430","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/art.33333","article-title":"Novel proteasome inhibitors have a beneficial effect in murine lupus via the dual inhibition of type I interferon and autoantibody secreting cells","volume":"64","author":"Ichikawa","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"2022","key":"10.1016\/j.bcp.2025.117018_b0435","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bcp.2025.117018_b0440","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1055\/s-0038-1669921","article-title":"Proteasome inhibition with bortezomib induces apoptosis of long-lived plasma cells in steroid-resistant or relapsed immune thrombocytopaenia","volume":"118","author":"Li","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bcp.2025.117018_b0445","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/0961203316686703","article-title":"The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis","volume":"26","author":"Zhang","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.bcp.2025.117018_b0450","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s10067-023-06559-y","article-title":"Bortezomib is efficacious in the treatment of severe childhood-onset neuropsychiatric systemic lupus erythematosus with psychosis: a case series and mini-review of B-cell immunomodulation in antibody-mediated diseases","volume":"42","author":"Modica","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.bcp.2025.117018_b0455","doi-asserted-by":"crossref","first-page":"A14","DOI":"10.1136\/lupus-2023-KCR.17","article-title":"LO-017 zetomipzomib (KZR-616) demonstrates anti-inflammatory and immunomodulatory potential in patients with active lupus with or without lupus nephritis: results from the open-label phase 1b\/2 MISSION study","volume":"10","author":"Rovin","year":"2023","journal-title":"Oral Present."},{"key":"10.1016\/j.bcp.2025.117018_b0460","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.3390\/jcm11206139","article-title":"Bruton\u2019s tyrosine kinase inhibitors: the next frontier of B-cell-Targeted therapies for cancer, autoimmune disorders, and multiple sclerosis","volume":"11","author":"Garg","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.bcp.2025.117018_b0465","first-page":"1835","article-title":"Efficacy, safety, and pharmacodynamic effects of the bruton\u2019s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial, arthritis","volume":"73","author":"Isenberg","year":"2021","journal-title":"Rheumatol"},{"key":"10.1016\/j.bcp.2025.117018_b0470","first-page":"1518","article-title":"Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: a phase 2 randomized controlled trial, arthritis","volume":"76","author":"Merrill","year":"2024","journal-title":"Rheumatol"},{"key":"10.1016\/j.bcp.2025.117018_b0475","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.berh.2017.10.003","article-title":"Role of interferons in SLE","volume":"31","author":"Bengtsson","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.bcp.2025.117018_b0480","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"CD1067 study investigators, sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bcp.2025.117018_b0485","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bcp.2025.117018_b0490","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000261","article-title":"Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus","volume":"5","author":"Riggs","year":"2018","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.bcp.2025.117018_b0495","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/09612033211014267","article-title":"Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus","volume":"30","author":"Furie","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.bcp.2025.117018_b0500","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","author":"Furie","year":"2019","journal-title":"The Lancet Rheumatology 1"},{"key":"10.1016\/j.bcp.2025.117018_b0505","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"TULIP-2 trial investigators, trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.bcp.2025.117018_b0510","first-page":"00071","article-title":"LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials","volume":"S0003\u20134967","author":"Morand","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bcp.2025.117018_b0515","doi-asserted-by":"crossref","first-page":"676","DOI":"10.51891\/rease.v9i1.8289","article-title":"THE application of therapy by the aba machine as a use in the autistic: learning possibilities with mathematical games","volume":"9","author":"Moura","year":"2023","journal-title":"REASE"},{"key":"10.1016\/j.bcp.2025.117018_b0520","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1093\/rheumatology\/kead416","article-title":"Role of IL-6 and IL-6 targeted therapy in systemic lupus erythematosus","volume":"62","author":"Nepal","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bcp.2025.117018_b0525","doi-asserted-by":"crossref","unstructured":"I. Gabor G., S. Yuko, Y. Cheryl H., D. Jimmy, T. Edward, T. Kazuki, F. Thomas, B. James E., L. Peter E., Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open\u2010label phase I dosage\u2010escalation study, Arthritis & Rheumatism 62 (2010) 542\u2013552. https:\/\/doi.org\/10.1002\/art.27221.","DOI":"10.1002\/art.27221"},{"key":"10.1016\/j.bcp.2025.117018_b0530","first-page":"2174","article-title":"Randomized, double\u2010blind, placebo\u2010controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis, arthritis","volume":"68","author":"Rovin","year":"2016","journal-title":"Rheumatol"},{"key":"10.1016\/j.bcp.2025.117018_b0535","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/annrheumdis-2016-209668","article-title":"Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial","volume":"76","author":"Wallace","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bcp.2025.117018_b0540","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/jth.12518","article-title":"Systemic lupus erythematosus increases the risks of deep vein thrombosis and pulmonary embolism: a nationwide cohort study","volume":"12","author":"Chung","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bcp.2025.117018_b0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102870","article-title":"Abnormalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies","volume":"132","author":"Li","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.bcp.2025.117018_b0550","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bcp.2025.117018_b0555","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15182","article-title":"Expanding the role of CAR T\u2010cell therapy: from B\u2010cell hematological malignancies to autoimmune rheumatic diseases","volume":"27","author":"Shumnalieva","year":"2024","journal-title":"Int J of Rheum Dis"},{"key":"10.1016\/j.bcp.2025.117018_b0560","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2025.117018_b0565","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.bcp.2025.117018_b0570","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2025.117018_b0575","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bcp.2025.117018_b0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.08.023","article-title":"Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy","volume":"31","author":"Nunez","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.bcp.2025.117018_b0585","article-title":"Evolving treatment strategies for systemic lupus erythematosus in clinical practice: a narrative review","volume":"16","author":"Kaye","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.bcp.2025.117018_b0590","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1476859","article-title":"CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.bcp.2025.117018_b0595","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70037","article-title":"A real-world study on adverse reactions of belimumab based on the FDA adverse event reporting system database","volume":"33","author":"Hai","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.bcp.2025.117018_b0600","first-page":"60","article-title":"Photoswitchable CAR-T cell function inVitro and inVivo via a cleavable mediator, cell","volume":"28","author":"Zhang","year":"2021","journal-title":"Chem Biol"},{"key":"10.1016\/j.bcp.2025.117018_b0605","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225002837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225002837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T06:56:02Z","timestamp":1752648962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225002837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":121,"alternative-id":["S0006295225002837"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117018","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B cell-targeted therapies in systemic lupus erythematosus: Current status and perspectives","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117018"}}